Nicolai Wagtmann

Nicolai Wagtmann has a diverse work experience in the field of scientific research and biotechnology. Nicolai served as the Chief Scientific Officer at Dragonfly Therapeutics, Inc. since July 2017. Prior to that, they held the position of Executive Vice President and Chief Scientific Officer at Innate Pharma from January 2014 to June 2017. Nicolai also worked at Novo Nordisk for several years, starting as a Research Scientist in October 1998 and progressing to roles such as Department Manager, Director, and Vice President until December 2013. Earlier in their career, they served as an INSERM Visiting Fellow at the Centre d'Immunologie de Marseille-Luminy from January 1998 to October 1998. Before that, they gained valuable experience at the National Institutes of Health as a Visiting Associate and Visiting Fellow, focusing on molecular cloning and characterization of genes related to Natural Killer cell function and tumor cell tolerance.

Nicolai Wagtmann received their high school education at Rungsted Statsskole from 1980 to 1982. Nicolai then pursued their undergraduate and graduate studies at Københavns Universitet - University of Copenhagen, earning their Cand. Scient and PhD degrees in Cellular and Molecular Immunology from 1984 to 1997. Prior to that, they attended the International School of Geneva from 1977 to 1980, although no specific degree or field of study is mentioned for that period.